Two Undervalued Healthcare Stocks with 60%+ Upside Potential
Two UNDERVALUED healthcare stocks that could run 60%+ in the next year?
Yes, please. 🚀
Who’s hunting for healthcare gems in this beat-up sector? 🙋♂️🙋♀️
These two are flying under the radar — let’s talk.
The healthcare sector has drastically underperformed the broader market over the past year. Yet, within the beaten-down space, several undervalued stocks now show strong upside potential. Some analysts believe these two companies could rally at least 60% in the next 12 months: Viking Therapeutics (VKTX) and HCA Healthcare (HCA).
$Viking Therapeutics(VKTX)$
Over the past few years, Viking Therapeutics has emerged as a high-profile name in biotechnology, driven by its pipeline of next-generation weight-loss drugs.
Since the FDA approved Novo Nordisk’s Wegovy in 2021, anti-obesity medications have boomed in the U.S. and other markets with high obesity rates.
What stands out with Viking is its lead drug candidate: VK2735, now in late-stage development. The company recently announced it has completed patient enrollment in a key Phase 3 trial, with data expected to be released next year. Viking is also developing an oral formulation of VK2735, with a Phase 3 trial set to begin in the third quarter of this year.
Early clinical data suggests VK2735 may deliver faster weight loss than Wegovy or Eli Lilly’s Zepbound, the current leaders in the market.
This late-stage positioning, strong efficacy, and massive commercial potential have investors and analysts bullish on Viking.
Several market watchers believe the stock could see multi-bagger upside — a common move for biotech firms when their first drug gains FDA approval.
Canaccord Genuity analyst Edward Nash set a $107 price target, implying more than 100% upside.
BTIG analyst Jeet Mukherjee is even more bullish, with a $125 target.
Investing in clinical-stage biotech companies carries high risk, as pipeline programs face binary success-or-failure events.
But based on VK2735’s encouraging clinical profile, the odds of regulatory approval and commercial success appear above the industry average.
$Hca Healthcare Inc(HCA)$
HCA Healthcare is the largest for-profit hospital operator in the United States, owning and managing 186 hospitals and roughly 2,400 outpatient clinics across the U.S. and the United Kingdom.
Rising patient volumes have boosted its strong fundamentals.
In the fourth quarter of 2025, same-hospital admissions rose 2.4% year-over-year, pushing total revenue up nearly 7% to $19.5 billion.
Management expects full-year revenue growth of up to 6% in 2026.
A powerful long-term driver is the aging U.S. population.
The 2020 U.S. Census recorded 55.8 million people aged 65 and older, making up 17% of the population — both all-time highs.
Market researcher Claritas projects this group will jump to 71.6 million by 2030, or 20.7% of the total population.
More seniors mean sharply higher demand for healthcare services.
As a leading provider, HCA is positioned to benefit directly from this megatrend.
At the same time, management is actively innovating to solve labor shortages, using its AI platform Timpani to optimize nurse staffing and ease the human-cap bottleneck in the U.S. healthcare system.
Conclusion
In short:
-
Viking Therapeutics benefits from its late-stage anti-obesity drug VK2735, strong clinical data, and massive commercial potential, with above-average odds of success.
-
HCA Healthcare rides the powerful wave of aging-driven healthcare demand, while using technology to boost operational efficiency.
Both are undervalued healthcare stocks with 60%+ upside ahead.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
